GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OliX Pharmaceuticals Inc (XKRX:226950) » Definitions » Debt-to-Revenue

OliX Pharmaceuticals (XKRX:226950) Debt-to-Revenue : 216.71 (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is OliX Pharmaceuticals Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

OliX Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩17,759 Mil. OliX Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩21,434 Mil. OliX Pharmaceuticals's annualized Revenue for the quarter that ended in Dec. 2024 was ₩181 Mil. OliX Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 216.71.


OliX Pharmaceuticals Debt-to-Revenue Historical Data

The historical data trend for OliX Pharmaceuticals's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OliX Pharmaceuticals Debt-to-Revenue Chart

OliX Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.87 10.06 4.72 2.31 6.90

OliX Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.94 15.24 2.60 45.90 216.71

Competitive Comparison of OliX Pharmaceuticals's Debt-to-Revenue

For the Biotechnology subindustry, OliX Pharmaceuticals's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OliX Pharmaceuticals's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OliX Pharmaceuticals's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where OliX Pharmaceuticals's Debt-to-Revenue falls into.


;
;

OliX Pharmaceuticals Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

OliX Pharmaceuticals's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(17758.638 + 21433.784) / 5677.152
=6.90

OliX Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(17758.638 + 21433.784) / 180.856
=216.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


OliX Pharmaceuticals Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of OliX Pharmaceuticals's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


OliX Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 1014 Gwanggyo Ace Tower 1, Daehak 4-ro, Yeongtong-gu, Gyeonggi, Suwon, KOR, 16226
OliX Pharmaceuticals Inc is a clinical stage biotechnology company. It is engaged in developing RNA interference (RNAi) technology therapeutics for dermal, ophthalmic and pulmonary diseases. The company's pipeline products include OLX101, OLX201, OLX301, OLX102, and others.

OliX Pharmaceuticals Headlines

No Headlines